The psychoactive mushroom Psilocybe cubensis, known for its historical and modern therapeutic roles, shows substantial variability in its psychoactive compounds, psilocybin and psilocin, due to genetic diversity, strain differences, and environmental factors. Advances in cultivation, such as submerged fermentation of mycelium, and improved analytical methods now allow more precise compound quantification and extraction. Despite nearly four decades of regulatory restrictions limiting scientific information, recent genetic and biochemical studies are beginning to reveal insights into its therapeutic potential. The review identifies key knowledge gaps and suggests future research directions to improve cultivation, document strain diversity, and address regulatory and therapeutic uses.
Even when grown under identical conditions, different strains of the same mushroom species, Psilocybe cubensis, vary dramatically in their psychedelic compound content. Total tryptamine concentrations ranged more than 7.8-fold across 14 strains, from 2.62 to 20.65 mg per gram of dried mushroom. Psilocybin was always the most abundant compound. Individual mushrooms from the same strain also showed substantial variation, with psilocybin levels differing by 12.81% to 23.39% between fruiting bodies. This biochemical variability, both between strains and within a single strain, makes it difficult to standardize whole mushroom preparations for research or therapeutic use, emphasizing the need for careful strain selection, chemical profiling, and precise dosing.